Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Go back to Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy| Capricor Therapeutics, Inc. (NASDAQ: CAPR) | Delayed: 19.47 -0.36 (1.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.83 | 52 Week High | $5.40 | |||
| Open | $19.77 | 52 Week Low | $1.88 | |||
| Day High | $20.18 | P/E | N/A | |||
| Day Low | $18.31 | EPS | $0.00 | |||
| Volume | 1,598,671 | |||||
